Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
SK-PC-B70M is an oleanolic-glycoside saponin-enriched fraction derived from the root of Pulsatilla koreana. Its active ingredient includes hederacolchiside-E, which has demonstrated neuroprotective and cognition-enhancing effects in preclinical studies. The compound has shown efficacy in improving memory consolidation and spatial working memory impairments induced by scopolamine in animal models, as well as reducing amyloid-beta (Aβ) levels and plaque deposition in transgenic mouse models of Alzheimer's disease. Additionally, it exhibits antioxidant properties by reducing lipid peroxidation by-products such as malondialdehyde (MDA) and 4-hydroxy-2-nonenal (HNE), suggesting a role in attenuating neurodegenerative pathology. Clinical development was primarily focused on Alzheimer's disease[1][2][5][6].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on SK-PC-B70M.